Axsome Therapeutics AXSM Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $638.5M+65.5% | $385.69M+42.5% | $270.6M+441% | $50.04M— | ||
| $47.48M+42.6% | $33.3M+27.8% | $26.07M+401% | $5.2M— | ||
| $591.02M+67.7% | $352.39M+44.1% | $244.54M+445% | $44.84M— | ||
| 92.6%+1.2pp | 91.4%+1.0pp | 90.4%+0.8pp | 89.6%— | ||
| $183.28M-2.0% | $187.08M+91.0% | $97.94M+69.0% | $57.95M-0.2% | ||
| $570.6M+38.7% | $411.36M+27.3% | $323.12M+103% | $159.25M+139% | ||
| $805.26M+20.9% | $666.26M+32.6% | $502.43M+119% | $229.84M+84.3% | ||
| -$166.76M+40.6% | -$280.56M-21.0% | -$231.83M-28.9% | -$179.8M-44.2% | ||
| -26.1%+46.6pp | -72.7%+12.9pp | -85.7%+274pp | -359.3%— | ||
| -$183.7M+36.0% | -$287.13M-20.5% | -$238.28M-27.3% | -$187.13M-43.5% | ||
| —— | $85K— | —— | —— | ||
| -$183.17M+36.2% | -$287.22M-20.1% | -$239.24M-27.8% | -$187.14M-43.5% | ||
| -28.7%+45.8pp | -74.5%+13.9pp | -88.4%+286pp | -374%— | ||
| -$3.68+38.6% | -$5.99-14.1% | -$5.25-13.6% | -$4.62-33.1% | ||
| -$159.88M+41.6% | -$273.64M-21.6% | -$224.99M-28.3% | -$175.4M-40.7% | ||
| -25%+45.9pp | -70.9%+12.2pp | -83.1%+267pp | -350.5%— | ||
| -$166.76M+40.6% | -$280.56M-21.0% | -$231.83M-28.9% | -$179.8M-44.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Axsome Therapeutics's revenue?
- Axsome Therapeutics (AXSM) generated $708.2M in revenue over the trailing twelve months, up 63.9% year over year.
- Is Axsome Therapeutics profitable?
- Axsome Therapeutics is not currently profitable: it reported a net loss of $188.3M over the trailing twelve months, a -26.6% net margin.
- What are Axsome Therapeutics's profit margins?
- Gross margin is 92.6% and operating margin is -24.4%, with a -26.6% net margin.
- What is Axsome Therapeutics's earnings per share?
- Axsome Therapeutics's diluted EPS over the trailing twelve months is $-3.72.
- Where does Axsome Therapeutics's income statement data come from?
- Every line is extracted from Axsome Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
